Recent Updates
Recently added Catalysts
DXCM Positive Sentiment

Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care

Monday, September 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Dexcom, Inc. has published its 'Dexcom State of Type 2 Report' ahead of the EASD 2026, focusing on global access and attitudes towards diabetes technology. The report reveals significant opportunities for improving diabetes care. Additionally, Dexcom announced a partnership with Team Novo Nordisk to serve as their official continuous glucose monitor.

Market Sentiment Analysis

POSITIVE FACTORS

  • Dexcom's report highlights critical opportunities in diabetes care.
  • The partnership with Team Novo Nordisk enhances brand visibility.
  • The report aims to improve global access to diabetes technology.

Full Press Release Details

MILAN--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its “Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology” in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28-Oct. 2. The company also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk. Dexcom releases 2026 edition of its State of Type 2 Repo

Frequently Asked Questions

What is the Dexcom State of Type 2 Report?

It is a report focusing on global access and attitudes towards diabetes technology.

When was the report released?

The report was released in advance of the EASD 2026 meeting in Milan.

What partnership did Dexcom announce?

Dexcom announced a partnership to be the official glucose monitor for Team Novo Nordisk.

What is the significance of the report?

The report reveals critical opportunities for improving global diabetes care.

ShareAdd on Google
Tags: DXCM Viatris Investor Conferences Healthcare Dexcom Type 2 Diabetes EASD 2026 glucose monitoring diabetes technology
Last updated: Sep 28, 2026

Biotech snapshot

Cash runway
$1947M liquidity · $0M/mo burn
Low dilution risk
Lead asset
The Seven Continuous Glucose Monitoring SystemPhase 1
Diabetes, Gestational →